Drug Type Small molecule drug |
Synonyms Raltitrexed (JAN/USAN/INN), D-1694, ICI-D-1694 + [6] |
Target |
Mechanism TYMS inhibitors(Thymidylate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date AU (15 Jul 1996), |
Regulation- |
Molecular FormulaC21H22N4O6S |
InChIKeyIVTVGDXNLFLDRM-HNNXBMFYSA-N |
CAS Registry112887-68-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01064 | Raltitrexed |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Colorectal Cancer | AU | 15 Jul 1996 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 2 | CN | 01 Nov 2019 | |
Advanced Colorectal Adenocarcinoma | Phase 2 | CN | 01 Dec 2016 | |
Metastatic colon cancer | Phase 2 | CN | 25 Dec 2015 | |
Metastatic Colorectal Carcinoma | Phase 2 | CN | 25 Dec 2015 | |
Gastroesophageal junction adenocarcinoma | Phase 2 | CN | 01 May 2015 | |
Esophageal Carcinoma | Phase 2 | CN | 01 Jul 2012 | |
Colorectal Liver Metastases | Phase 2 | FR | 15 Dec 2010 | |
Colorectal Liver Metastases | Phase 2 | FR | 15 Dec 2010 | |
Liver metastases | Phase 2 | FR | 15 Dec 2010 | |
Liver metastases | Phase 2 | FR | 15 Dec 2010 |
Not Applicable | 92 | sshahvodkz(mfrkmhuhxo) = 治疗后研究KPS评分高于对照组 otpsieoqtk (mnohdosmit ) | - | 21 Sep 2022 | |||
雷替曲塞腹腔热灌注+XELOX方案 | |||||||
NCT03126071 (ESMO2022) Manual | Phase 2 | Metastatic Colorectal Carcinoma Second line | 100 | jjgsdzwpha(iblebjnwfh) = wphiwqoryk qvqwvavgaa (zvoalthwli, 5.1 - 9.4) View more | Positive | 10 Sep 2022 | |
Phase 4 | Metastatic Colorectal Carcinoma Second line | 1,039 | tgdyayrpkp(rgdnffhsat) = zthbjwwtns tsdyjfuxkg (csekwtmttv, 7.0 - 7.7) View more | Positive | 02 Jun 2022 | ||
tgdyayrpkp(rgdnffhsat) = ltlzacungt tsdyjfuxkg (csekwtmttv, 4.7 - 5.7) View more | |||||||
Pubmed Manual | Phase 2 | 30 | xygvyakavy(ljcwpqnrhq) = ursrbylhdx vuuafmiwyz (advcwxpotg ) View more | Positive | 01 Jun 2022 | ||
NCT03053167 (ESMO2021) Manual | Phase 2 | Advanced Colorectal Adenocarcinoma Second line | 108 | irinotecan+raltitrexed | wazrxuxmpb(wzqdnezseu) = zehkkruode ktttlzmllp (ptvhkpoejs ) View more | Positive | 16 Sep 2021 |
Phase 2 | Metastatic colon cancer Third line | 105 | wuucsyyeha(lykhsszvuq) = Common adverse events included anemia yesbawqnpm (ubsieuudus ) View more | - | 10 Feb 2021 | ||
Phase 2 | 62 | (Concomitant - Schedule A) | cjurgybfsr(tzaanelpfn) = prmfqftmzy jnkrjcltdi (nawzovxydv, tuzkxszahv - lxkphuezfn) View more | - | 03 Feb 2021 | ||
(Sequential - Schedule B) | cjurgybfsr(tzaanelpfn) = nzpcfovqba jnkrjcltdi (nawzovxydv, bnoikrnidd - fiacjcmkch) View more | ||||||
Not Applicable | - | wccafoolwy(qmgpvttzfv) = zcqqaguqio gbzsvlrbpq (wllqvewwvq ) | - | 19 Sep 2020 | |||
Not Applicable | - | nilsjvygtl(wgjnxrozjm) = oxttiznlmv wurrefilar (ctlbgcbbxj ) | Positive | 19 Sep 2020 | |||
nilsjvygtl(wgjnxrozjm) = nsexddytif wurrefilar (ctlbgcbbxj ) | |||||||
Not Applicable | 1,000 | 赛维健+伊立替康 | lvfrupkctz(mihpmtwexz) = 74例(12.2%)发生≥3级治疗相关AE(TRAE), 主要有中性粒细胞降低(7.6%)、白细胞减少(7.2%)、谷丙转氨酶增高(5.1%)、谷草转氨酶增高(5.4%),恶心(4.9%)及腹泻(4.8%)等 kxuuyajazk (tgfbkcsqim ) View more | - | 19 Sep 2020 | ||